恩和生物獲紅杉中國領投逾1億美元融資 美團(03690.HK)跟投
內地工業合成生物技術公司恩和生物(Bota Biosciences)宣布,近日完成由紅杉中國領投的B輪融資,涉及逾1億美元,招銀國際資本及現有投資者經緯中國、夏爾巴投資、源碼資本、五源資本及美團(03690.HK)等跟投。
恩和生物表示,至今融資總額已超過1.45億美元,是次所得資金將用於擴展全球業務,進一步完善Bota Freeway和高精度發酵平台以及中試工廠的搭建,進一步擴展消費品、食品、營養品和醫藥領域產品管線。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.